{"id":745538,"date":"2017-06-04T08:00:00","date_gmt":"2017-06-04T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/"},"modified":"2025-11-07T01:26:27","modified_gmt":"2025-11-07T06:26:27","slug":"with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/","title":{"rendered":"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure"},"content":{"rendered":"<p class=\"bwalignc\">       Findings to Be Presented at 2017 ASCO Annual Meeting Also Include        Updated Data Evaluating Duration of Response in Previously Untreated        (First-Line) Urothelial Carcinoma Patients Ineligible for        Cisplatin-Based Therapy     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced updated results from KEYNOTE-045 and KEYNOTE-052, two<br \/>\n      studies investigating KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the<br \/>\n      company\u2019s anti-PD-1 therapy, in certain patients with locally advanced<br \/>\n      or metastatic urothelial carcinoma, a type of bladder cancer. These data<br \/>\n      \u2013 which include updated survival and biomarker analyses \u2013 demonstrate<br \/>\n      the clinical benefit of KEYTRUDA as a second-line therapy for patients<br \/>\n      post-platinum failure and as a first-line treatment for patients<br \/>\n      ineligible for cisplatin-based therapy. Specifically, in the second-line<br \/>\n      setting, KEYTRUDA improved overall survival (OS) compared to<br \/>\n      chemotherapy \u2013 reducing the risk of death by 30 percent (HR, 0.70 [95%<br \/>\n      CI, 0.57-0.86], p = 0.0004) \u2013 and, in the first-line setting, KEYTRUDA<br \/>\n      demonstrated an overall response rate (ORR) of 29 percent (95% CI,<br \/>\n      25-34). Findings will be presented in two oral sessions at the 2017<br \/>\n      American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago<br \/>\n      on Monday, June 5, from 8:12 to 8:36 a.m. CDT (Location: Arie Crown<br \/>\n      Theater) (Abstracts #4501 and #4502).\n    <\/p>\n<p>\n      \u201cHistorically, there have been limited treatment options for patients<br \/>\n      with advanced urothelial bladder cancer,\u201d said Dean F. Bajorin, M.D.,<br \/>\n      medical oncologist at Memorial Sloan Kettering Cancer Center. \u201cFor<br \/>\n      patients with this devastating disease, the efficacy and safety profile<br \/>\n      we have observed with KEYTRUDA in these treatment settings represent an<br \/>\n      important new option.\u201d\n    <\/p>\n<p>\n      \u201cThe updated data at ASCO in previously treated urothelial cancer<br \/>\n      patients continue to support the overall survival benefit we have<br \/>\n      observed in the second-line treatment setting and the response rates<br \/>\n      demonstrated in cisplatin-ineligible patients,\u201d said Dr. Roger Dansey,<br \/>\n      senior vice president and therapeutic area head, oncology late-stage<br \/>\n      development, Merck Research Laboratories. \u201cBeyond these two studies, we<br \/>\n      are studying KEYTRUDA in other treatment settings and look forward to<br \/>\n      executing on our robust clinical development program in bladder cancer.&#8221;\n    <\/p>\n<p>\n      The KEYTRUDA (pembrolizumab) clinical development program includes more<br \/>\n      than 30 tumor types in more than 500 clinical trials, including more<br \/>\n      than 300 trials that combine KEYTRUDA with other cancer treatments.<br \/>\n      Currently, Merck has the largest immuno-oncology clinical development<br \/>\n      program in bladder cancer, with 29 trials underway involving KEYTRUDA as<br \/>\n      monotherapy and in combination, including four registration-enabling<br \/>\n      studies.\n    <\/p>\n<p>\n      <b>Data in Second-Line Post-Platinum Failure Patients, KEYNOTE-045<br \/>\n      (Abstract #4501)<\/b>\n    <\/p>\n<p>\n      KEYNOTE-045 is a multicenter, randomized, active-controlled, phase 3<br \/>\n      trial, investigating KEYTRUDA in 542 patients with locally advanced or<br \/>\n      metastatic urothelial carcinoma with disease progression on or after<br \/>\n      platinum-containing chemotherapy (additional details on the trial design<br \/>\n      are provided below). Data to be presented at ASCO are based on longer<br \/>\n      follow-up (median follow-up of 18.5 months as of Jan. 18, 2017; range:<br \/>\n      14.2-26.5), which continues to show a superior OS advantage with<br \/>\n      KEYTRUDA compared to chemotherapy in the second-line treatment of<br \/>\n      patients with advanced urothelial carcinoma who have progressed during<br \/>\n      or following platinum-containing chemotherapy, regardless of PD-L1<br \/>\n      expression.\n    <\/p>\n<p>\n      Analyses of the primary endpoints showed a 30 percent reduction in the<br \/>\n      risk of death with KEYTRUDA (n=270) compared to chemotherapy (n=272)<br \/>\n      (HR, 0.70 [95% CI, 0.57-0.86], p = 0.0004). The median OS with KEYTRUDA<br \/>\n      was 10.3 months (95% CI, 8.0-12.3) versus 7.4 months with chemotherapy<br \/>\n      (95% CI, 6.1-8.1). As previously reported, there was no significant<br \/>\n      improvement in progression-free survival (PFS) between arms (HR, 0.96<br \/>\n      [95% CI, 0.79-1.16], p= 0.32). The median PFS was 2.1 months (95% CI,<br \/>\n      2.0-2.2) in the KEYTRUDA arm and 3.3 months (95% CI, 2.4-3.5) in the<br \/>\n      chemotherapy arm. The six-month, 12-month and 18-month PFS rates in the<br \/>\n      KEYTRUDA arm were 28.8 percent, 17.6 percent and 16.8 percent,<br \/>\n      respectively; the six-month, 12-month and 18-month PFS rates in the<br \/>\n      chemotherapy arm were 28.4 percent, 7.9 percent and 3.5 percent,<br \/>\n      respectively.\n    <\/p>\n<p>\n      Analyses of the secondary endpoints showed a higher ORR with KEYTRUDA<br \/>\n      compared to chemotherapy. In patients treated with KEYTRUDA, the ORR was<br \/>\n      21.1 percent \u2013 with a complete response rate of 7.8 percent and a<br \/>\n      partial response rate of 13.3 percent. In patients treated with<br \/>\n      chemotherapy, the ORR was 11.0 percent \u2013 with a complete response rate<br \/>\n      of 2.9 percent and a partial response rate of 8.1 percent. The median<br \/>\n      duration of response had not been reached in the KEYTRUDA<br \/>\n      (pembrolizumab) arm (range: 1.6+-20.7+) and was 4.4 months in the<br \/>\n      chemotherapy arm (range: 1.4+-20.3+).\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies. Grade 1-2 treatment-related adverse events<br \/>\n      in the KEYTRUDA arm included anemia, asthenia, constipation, decreased<br \/>\n      appetite, diarrhea, fatigue, nausea, peripheral neuropathy, peripheral<br \/>\n      sensory neuropathy and pruritus. Grade 3-5 treatment-related adverse<br \/>\n      events in the KEYTRUDA arm included anemia, asthenia, decreased<br \/>\n      neutrophils, diarrhea, fatigue, nausea and pruritus. Grade 3-5<br \/>\n      immune-mediated adverse events included adrenal insufficiency, colitis,<br \/>\n      nephritis, pneumonitis and severe skin reaction.\n    <\/p>\n<p>\n      <b>Data in First-Line Cisplatin-Ineligible Patients, KEYNOTE-052<br \/>\n      (Abstract #4502)<\/b>\n    <\/p>\n<p>\n      KEYNOTE-052 is a multicenter, open-label, single-arm phase 2 trial,<br \/>\n      investigating KEYTRUDA in 370 patients with locally advanced or<br \/>\n      metastatic urothelial carcinoma who were not eligible for<br \/>\n      cisplatin-containing chemotherapy (additional details on the trial<br \/>\n      design are provided below). Findings to be presented at ASCO, which<br \/>\n      include the full study population and longer follow-up, show that in the<br \/>\n      first-line treatment setting many patients with cisplatin-ineligible<br \/>\n      advanced urothelial carcinoma treated with KEYTRUDA continue to<br \/>\n      experience complete or partial responses.\n    <\/p>\n<p>\n      In the full study population (n=370), the efficacy analysis showed an<br \/>\n      ORR of 29 percent (95% CI, 25-34) \u2013 with a complete response rate of<br \/>\n      seven percent (95% CI, 5-10) and a partial response rate of 22 percent<br \/>\n      (95% CI, 18-27). At the time of analysis, 67 percent of responses were<br \/>\n      ongoing \u2013 of which 82 percent had lasted six months or longer. The<br \/>\n      median duration of response had not been reached at the time of analysis<br \/>\n      (95% CI, 12 months-not reached).\n    <\/p>\n<p>\n      The study included a training set (the first 100 patients enrolled),<br \/>\n      which was used to identify the CPS cut-point for PD-L1 expression, and a<br \/>\n      validation set (which includes all subsequent 270<b> <\/b>evaluable<br \/>\n      patients) intended to validate the combined positive score (CPS)<br \/>\n      cut-point. Of the 270 patients in the validation set, in patients with<br \/>\n      PD-L1 expression of less than 10 percent (CPS &lt;10%), the ORR was 23<br \/>\n      percent (95% CI, 17-29), with a complete response rate of three percent<br \/>\n      (95% CI, 1-6) and a partial response rate of 20 percent (95% CI, 15-27);<br \/>\n      in patients expressing PD-L1 equal to or greater than 10 percent (CPS<br \/>\n      \u226510%), the ORR was 51 percent (95% CI, 40-63), with a complete response<br \/>\n      rate of 18 percent (95% CI, 10-28) and a partial response rate of 34<br \/>\n      percent (95% CI, 24-45).\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies. The treatment-related adverse events (any<br \/>\n      grade occurring in 5% or more of patients [n=370] in descending order)<br \/>\n      were fatigue (18%), pruritus (17%), rash (12%), decreased appetite<br \/>\n      (10%), hypothyroidism (10%), diarrhea (9%), and nausea (8%). Grade 3-5<br \/>\n      treatment-related adverse events observed (occurring in 3 or more of<br \/>\n      patients) were fatigue (2%), colitis (2%), muscle weakness (1%),<br \/>\n      alkaline phosphatase increase (1%), diarrhea (1%), pneumonitis (1%), AST<br \/>\n      increase (1%), asthenia (1%), hepatitis (1%), and ALT increase (1%).<br \/>\n      Grade 3-5 immune-mediated adverse events included: adrenal<br \/>\n      insufficiency, colitis, dermatitis bullous, diabetic ketoacidosis,<br \/>\n      hepatitis, myocarditis, pneumonitis, thyroiditis, type 1 diabetes<br \/>\n      mellitus, tubulointerstitial nephritis and rash.\n    <\/p>\n<p>\n      <b>About the KEYNOTE-045 and KEYNOTE-052 Studies<\/b>\n    <\/p>\n<p>\n      KEYNOTE-045 is a multicenter, randomized, active-controlled, phase 3<br \/>\n      trial, investigating KEYTRUDA (pembrolizumab) in 542 patients with<br \/>\n      locally advanced or metastatic urothelial carcinoma with disease<br \/>\n      progression on or after platinum-containing chemotherapy. Patients were<br \/>\n      randomized to receive either KEYTRUDA 200 mg every three weeks (n=270)<br \/>\n      or investigator\u2019s choice of any of the following chemotherapy regimens,<br \/>\n      all given intravenously, every three weeks (n=272): paclitaxel 175 mg\/m<sup>2<\/sup><br \/>\n      (n=84), docetaxel 75 mg\/m<sup>2 <\/sup>(n=84), or vinflunine 320 mg\/m<sup>2<\/sup><br \/>\n      (n=87). Treatment continued until unacceptable toxicity or disease<br \/>\n      progression; patients without disease progression could be treated for<br \/>\n      up to 24 months. The primary endpoints were OS and PFS, as assessed by<br \/>\n      blinded independent central review (BICR) per RECIST (Response<br \/>\n      Evaluation Criteria in Solid Tumors) v1.1; additional efficacy outcome<br \/>\n      measures included ORR, as assessed by BICR per RECIST 1.1, and duration<br \/>\n      of response. Efficacy was assessed in all patients, as well as in<br \/>\n      patients with PD-L1 expression \u2013 as determined by a CPS of equal to or<br \/>\n      greater than 10 percent (CPS \u226510%) (KEYTRUDA arm: n=74\/270; chemotherapy<br \/>\n      arm; n=90\/272).\n    <\/p>\n<p>\n      KEYNOTE-052 is a multicenter, open-label, single-arm phase 2 trial,<br \/>\n      investigating KEYTRUDA in 370 patients with locally advanced or<br \/>\n      metastatic urothelial carcinoma who were not eligible for<br \/>\n      cisplatin-containing chemotherapy. Patients received KEYTRUDA at a dose<br \/>\n      of 200 mg every three weeks until unacceptable toxicity or disease<br \/>\n      progression; patients without disease progression could be treated for<br \/>\n      up to 24 months. The study included a training set (the first 100<br \/>\n      patients enrolled), which was used to identify the CPS cut-point for<br \/>\n      PD-L1 expression, and a validation set, which includes all subsequent 270<b><br \/>\n      <\/b>evaluable patients and will be used to validate the CPS cut-point.<br \/>\n      The primary endpoints include ORR in all patients enrolled in the study<br \/>\n      (total study population) and in patients with PD-L1 positive tumors<br \/>\n      (expression of one percent or more); secondary endpoints include<br \/>\n      duration of response, PFS and OS. Tumor response was measured according<br \/>\n      to RECIST v1.1 by central imaging vendor review.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single-dose vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA (pembrolizumab) is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA<br \/>\n      (pembrolizumab) is administered at a fixed dose of 200 mg every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA (pembrolizumab) for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA (pembrolizumab) when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA (pembrolizumab) can cause<br \/>\n      fetal harm when administered to a pregnant woman. If used during<br \/>\n      pregnancy, or if the patient becomes pregnant during treatment, apprise<br \/>\n      the patient of the potential hazard to a fetus. Advise females of<br \/>\n      reproductive potential to use highly effective contraception during<br \/>\n      treatment and for 4 months after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in\u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (20%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=7bcd97e1253f23ae5f36543bc1a650a5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=3d05acd6c8be7256e77313bf69f9871a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=dd4e170f7c509c9832f3525c9eb50b99\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=df4b2a3fe440cf985f3979ec4cfb2182\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=256634f5928ff467296114d64aff9597\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=196450e349993f1e8f50d59f2c0f583d\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=586cae06dc4d6d722dc10925d2e59ba1\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=ec09fdd75ef45403f1983882070a6705\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=45f4ab9aacd0743440753cc57575b22a\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51569385&amp;newsitemid=20170604005032&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=f8c177171d6941a213a503e6d2ab8a02\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170604005032r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck &amp; Co., Inc.<br \/> Media: <br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-740-6132<br \/>or<br \/> Investors: <br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Findings to Be Presented at 2017 ASCO Annual Meeting Also Include Updated Data Evaluating Duration of Response in Previously Untreated (First-Line) Urothelial Carcinoma Patients Ineligible for Cisplatin-Based Therapy Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-045 and KEYNOTE-052, two studies investigating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. These data \u2013 which include updated survival and biomarker analyses \u2013 demonstrate the clinical benefit of KEYTRUDA as a second-line therapy for patients post-platinum failure and as a first-line treatment for patients ineligible for cisplatin-based therapy. Specifically, in the second-line setting, KEYTRUDA improved overall survival (OS) compared to chemotherapy \u2013 reducing the risk of death by 30 percent (HR, 0.70 [95% CI, 0.57-0.86], p = 0.0004) \u2013 and,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,55,289],"class_list":["post-745538","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Findings to Be Presented at 2017 ASCO Annual Meeting Also Include Updated Data Evaluating Duration of Response in Previously Untreated (First-Line) Urothelial Carcinoma Patients Ineligible for Cisplatin-Based Therapy Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-045 and KEYNOTE-052, two studies investigating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. These data \u2013 which include updated survival and biomarker analyses \u2013 demonstrate the clinical benefit of KEYTRUDA as a second-line therapy for patients post-platinum failure and as a first-line treatment for patients ineligible for cisplatin-based therapy. Specifically, in the second-line setting, KEYTRUDA improved overall survival (OS) compared to chemotherapy \u2013 reducing the risk of death by 30 percent (HR, 0.70 [95% CI, 0.57-0.86], p = 0.0004) \u2013 and,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"21 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\\\/\",\"name\":\"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-06-04T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure - Merck.com","og_description":"Findings to Be Presented at 2017 ASCO Annual Meeting Also Include Updated Data Evaluating Duration of Response in Previously Untreated (First-Line) Urothelial Carcinoma Patients Ineligible for Cisplatin-Based Therapy Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-045 and KEYNOTE-052, two studies investigating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. These data \u2013 which include updated survival and biomarker analyses \u2013 demonstrate the clinical benefit of KEYTRUDA as a second-line therapy for patients post-platinum failure and as a first-line treatment for patients ineligible for cisplatin-based therapy. Specifically, in the second-line setting, KEYTRUDA improved overall survival (OS) compared to chemotherapy \u2013 reducing the risk of death by 30 percent (HR, 0.70 [95% CI, 0.57-0.86], p = 0.0004) \u2013 and,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:27+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"21 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/","name":"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-06-04T08:00:00+00:00","dateModified":"2025-11-07T06:26:27+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/with-more-than-one-year-follow-up-mercks-keytruda-pembrolizumab-shows-continued-overall-survival-benefit-over-chemotherapy-as-second-line-treatment-for-advanced-urothelial-carcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"With More than One-Year Follow-Up, Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"086ac8eb-aa1a-404b-b986-ed8693c17640","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/With-More-than-One-Year-Follow-Up-Mercks-KEYTRUDA-pembrolizumab-Shows-Continued-Overall-Survival-Benefit-Over-Chemotherapy-as-Second--6L9LS.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745538\/revisions"}],"predecessor-version":[{"id":3674894,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745538\/revisions\/3674894"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745538"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}